ERBB2 and breast cancer: The biological changes that occur during CDK4/6 inhibition were assessed in T47D (HR+/HER2-/HER2-enriched), MCF7 (HR+/HER2-/Luminal B), and BT474 (HR+/HER2+ /HER2-enriched) breast cancer cell lines.